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Increased body weight caused by visceral fat accumulation is on the rise and is reaching 
epidemic proportions worldwide. Hence, means and ways to tackle the problem of 
increased adiposity is of utmost importance. In this work, we report the effect of a water-
soluble small molecule N,N-Dimethlyacetamide (DMA) on weight gain and adiposity in vitro 
and in vivo. To monitor the in vitro effect of DMA on adipogenesis, 3T3-L1 preadipocytes 
and pluripotent C2C12 cells were differentiated to adipocytes in the presence of DMA (5 
mM and 10 mM). Oil red O staining and reverse transcriptase polymerase chain reaction 
(RT-PCR) were performed to evaluate the differentiation to adipocytes. To study the in 
vivo effect of DMA on body weight, experiments were done with C57BL/6J male mice 
(6 weeks old). The mice were randomly assigned to receive either high-fat diet (HFD; 
45% fat) or a normal diet (7% fat) and were either intraperitoneally injected with DMA 
or phosphate-buffered saline (PBS) once a week for 20 weeks. Glucose tolerance test 
was performed on living mice. Post-experiment, the epididymal and subcutaneous 
adipose tissue were excised from the sacrificed animal, and histology, RT-PCR and 
plasma triglyceride assay were performed. DMA had no inhibitory effect on adipocyte 
differentiation when applied only once. However, sustained treatment with DMA inhibited 
the adipocyte differentiation in both 3T3-L1 and C2C12 cells, and significantly lowered 
the expression of adipocyte markers, in particular, fatty acid-binding protein 4 (fabp4). 
Under HFD, C57BL/6J mice treated with DMA had lower body weight compared with 
PBS treatment. Moreover, the HFD-induced higher body weight was controlled when the 
mice were switched from PBS to DMA treatment. Further, the HFD-mediated adipocyte 
hypertrophy from epididymal and subcutaneous adipose tissue was significantly reduced 
with DMA treatment. Interestingly, the glucose clearance and triglyceride levels in the 
plasma were improved in mice when DMA treatment was initiated early. Taken together, 
our results show that DMA exhibits a clear potential to prevent weight gain and restricts 
adiposity in response to high-fat feeding.
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INTrODUcTION
Increased body weight in both children and in adults due to 
high visceral fat deposition is a major health concern. Over the 
last 40 years, the global prevalence of overweight and abdominal 
obesity has risen in both developed and developing countries, 
mainly in the cities (Ng et al., 2014). A detailed policy paper 
forecasting life expectancy suggest that if the present trend 
of overweight/obesity continues then increased body mass 
index (BMI) would be the topmost contributor for reduced life 
expectancy (Foreman et al., 2018). It is now well established 
that obesity/overweight is associated with major non-
communicable metabolic diseases like diabetes, cardiovascular 
diseases and certain forms of cancer. Moreover, the bone health 
is often deteriorated in individuals with increased fat mass 
(Shapses et al., 2017). The prevalence of vertebral fractures are 
higher in individuals with obesity (Rudman et al., 2019) and 
the occurrence of osteoporosis, particularly in postmenopausal 
women, is associated with increased body weight (Hsu et al., 
2006). High-fat diet-induced body weight gain enhance bone 
resorption and elevate osteoclasts in bone marrow (Cao et al., 
2010). Indeed lifestyle changes such as calorie restriction along 
with exercise has been reported to reduce fat mass, improve 
bone health and other cardio-metabolic parameters (Villareal 
et al., 2011; Styner et al., 2017: Oh et al., 2018).
Work from our group have shown that small molecules 
like NMP (N-methyl pyrrolidone) and DMA (N,N-
Dimethylaceteamide) which are used for drug delivery are also 
inherently bioactive (Gjoksi et al., 2016; Ghayor et al., 2017). 
We recently showed that DMA, a water-miscible solvent and a 
FDA approved excipient is epigenetically active and inhibits 
osteoclastogenesis and inflammation (Ghayor et al., 2017). 
Others have also shown that DMA reduces inflammation-
induced preterm birth (Gorasiya et al., 2018), which is mediated 
by inhibiting the nuclear factor-κB pathway (Pekson et al., 2016).
Using ovariectomized rats where estradiol depletion increases 
body weight, we have demonstrated that DMA blocks the body 
weight increase (Ghayor et al., 2017). Since ovariectomy is an 
artificial model leading to weight gain, hence in this work we asked 
the question if the bioactive small molecule DMA could control 
or prevent the weight gain induced by high-fat diet feeding.
MaTerIals aND MeTHODs
cell culture and Differentiation
3T3-L1 cells were cultured and differentiated at 37°C and 5% CO2, 
as previously described (Bhattacharya et al., 2015). Briefly, 3T3-L1 
cells purchased from American Type Culture Collection (ATCC, 
Manassas, VA, USA) were grown to confluence in Dulbecco’s 
modified Eagle’s medium (DMEM+GlutaMax-1; GIBCO, Grand 
Island, USA) with 10% new born calf serum (NBCS, Gibco, New 
Zealand) and antibiotics (100 U/ml penicillin G and 100 mg/
ml streptomycin). 2 days post-confluence, the induction media 
(IM) comprising of 3-isobutyl-1 methylxanthine (0.5 mM), 
dexamethasone (0.25 μM), insulin (10 μg/ml) and rosiglitazone 
(2 μM) in DMEM with 10% fetal bovine serum (FBS) was 
applied. The components of IM are also referred as MDIR in 
the manuscript. The IM was replaced after 2  days with the 
differentiation media (DM) comprising of DMEM with 10% FBS 
and insulin (1 μg/ml). Thereafter throughout the differentiation, 
the DM was changed every 2nd day.
N, N-Dimethylacetamide (DMA) anhydrous with 99.8% 
purity (Sigma-Aldrich Chemie GmbH, St. Gallen, Switzerland) 
was used for the experiments. DMA at 5mM and 10mM was 
added for these durations: a) Throughout: from day 0 to day 10; 
b) Post-Induction: from day 2 to day 10; c) Only once with IM: 
day 0 to day 2 and d) Post-differentiation: from day 10 to day 20.
C2C12 cells were cultured and differentiated at 37°C and 
5% CO2, as previously described (Qi et al., 2017). C2C12 cells 
(ATCC, Manassas, VA, USA) were cultured in DMEM media 
supplemented with 10% FBS and antibiotics (100 U/ml penicillin 
G and 100 mg/ml streptomycin). Once confluent, cells were 
treated in a similar manner like 3T3-L1 cells. DMA (5 and 
10 mM) was added throughout the differentiation period.
Oil red O staining
Staining with Oil red O was done as previously described (Gjoksi 
et al., 2016). Briefly, cells fixed with 10% formalin were washed with 
60% isopropanol and were subsequently stained with 0.5% Oil red 
O for 10 min. The non-specific staining was washed with water. For 
quantification, 100% isopropanol was applied to the stained cells and 
the stain was eluted, and the absorbance was measured at 500 nm.
Mice
Four weeks old, male C57BL/6J mice were procured from 
Charles River Laboratory (Sulzfeld, Germany). Three mice per 
cage were housed at the institutional animal facilities (University 
Hospital Zurich, Switzerland) with a 12-h light/dark cycle. At 6 
weeks of age, the mice were randomly given either standard chow 
(7% calories from fat; Kliba Nafag, Kaiseraugust, Switzerland) or 
high-fat diet (HFD; 45% calories from fat; Research Diets, Inc. 
New Brunswick, NJ, USA) for 20 weeks and water ad libitum. The 
mice fed with standard chow or HFD were either intraperitoneally 
injected with Dulbecco’s phosphate buffered saline (PBS; Gibco, 
Thermo Fisher Scientific, MA, USA) or with DMA (99.8% purity, 
Sigma-Aldrich Chemie, GmbH, Switzerland) once a week. DMA 
injected was 1/4th the dose of LD50 (ml/kg) as previously described 
(Bartsch et al., 1976). Before sacrificing, mice were weighed and 
put to sleep by exposing to CO2 and sacrifice was done by cervical 
dislocation. The local authorities (Kantonales Veterinaeramt of 
Zurich, Switzerland) approved the animal experiments.
Reverse Transcription Quantitative Polymerase 
Chain Reaction Analysis
RNA was extracted by scrapping the cells from the plate, 
as described earlier (Bhattacharya et al., 2015). RNA from 
epididymal adipose tissue was extracted after homogenizing 
the adipose tissue using homogenizer (Qiagen, Hombrechtikon, 
Switzerland). Briefly, RNeasy® lipid tissue kit was used to extract 
RNA from adipocytes as per the protocol of the manufacturer 
(Qiagen, Hombrechtikon, Switzerland). RNA quantity was 
determined using Nanodrop 2000 Spectrophotometer. Reverse 
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transcription of 1 µg RNA was perfomed using iScript™ 
Reverse Transcription Supermix according to manufacturer’s 
recommendations (BioRad, Hercules, CA, USA). Polymerase 
chain reaction was performed with each sample in duplicates 
using Bio-Rad CFX96 Real-Time System and iQ™ SYBR® Green 
Supermix (BioRad, Hercules, CA, USA) using specific primers. 
Gene expression was normalized to the reference gene ribosomal 
protein s18 (rps18) using the comparative CT method.
Primers
The primers that were used in this study were commercially 
available and was purchased from Qiagen. All the primers were 
specific to mouse (Table 1).
glucose Tolerance Test
The glucose tolerance test was done as described earlier (Mundy 
et al., 2007). Briefly, the mice were starved overnight with access 
to water and starving blood glucose was measured. Glucose 
(2mg/g) body weight was injected intraperitoneally and blood 
glucose levels were measured at 15, 30, 60, 90, 120 min. The 
starving blood glucose (mmol/L) was measured using Accu-
Chek Aviva Blood glucose meter (Roche Diabetes Care GmbH, 
Mannheim, Germany).
Histology
The paraffin sections of the epididymal and subcutaneous 
adipose tissue, and liver samples were processed and stained with 
hematoxylin and eosin. The sections were visualized by using 
the Olympus CKX53 microscope and the images were captured 
using the software Olympus CellSense Entry 1.16.
Triglyceride assay
The levels of triglyceride in the plasma were measured using 
the commercial available triglyceride assay kit (ab65336) from 
Abcam (Cambridge, UK). All the steps were followed as per the 
instructions in the manual.
statistical analysis
Data are expressed as means ± standard error of the mean 
(SEM). Comparisons between groups were analyzed by 
two-tailed Student’s t-test. Differences were considered 
statistically significant at values of P < 0.05. The sample size was 
determined by power analysis using the online G*Power tool 
(Heinrich Heine Universität Düsseldorf, Germany).
All statistical analysis was performed using GraphPad Prism 
5.04 program for Windows (GraphPad software, San Diego, 
CA, USA).
resUlTs
DMa Inhibits adipogenesis
The 3T3-L1 preadipocytes were differentiated to adipocytes in the 
presence of the differential cocktail (MDIR). When 5 mM or 10 
mM DMA was given throughout the differentiation process from 
day 0 to day 10 (Figure 1A), the differentiation was inhibited in a 
concentration-dependent manner (Figure 1B). DMA 5 mM and 
10 mM inhibited differentiation by 1.8- and 3.8-fold, respectively. 
In the absence of MDIR, the cells did not differentiate.
When 5 mM or 10 mM DMA was applied post-induction 
of differentiation from Day 2 to Day 10 (Figure 1C), the 
differentiation was inhibited but by a lesser degree. DMA 5 
mM and 10 mM inhibited the differentiation by 1.2- and 1.8-
fold, respectively (Figure 1D). When DMA was applied only 
once during the induction of differentiation (Figure 1E), the 
differentiation was unaffected either by 5mM or 10mM DMA 
(Figure 1F). To examine if DMA had an effect on differentiated 
adipocytes, DMA applied from day 10 to day 20 (Figure 1G) 
caused only a marginal reduction in differentiation with 10mM 
DMA (Figure 1H), as determined by Oil Red O staining (1.1-
fold; p = 0.01; Figure 1H).
DMa lowers the gene expression of 
adipocyte Markers
Differentiated cells expressed high levels of adipocyte marker, 
fatty acid binding protein 4 (Fabp4). In the presence of 5mM 
or 10mM DMA, the Fabp4 gene expression was reduced 
significantly in a concentration-dependent manner (Figure  2). 
The gene expression of PPARγ, a known marker expressed during 
early stages of adipocyte differentiation was significantly reduced 
by 10mM DMA. The inflammatory marker IL-6 was lowered by 
both 5mM and 10mM DMA. Adiponectin expression was not 
altered by DMA.
DMa Inhibits lipid Droplet Formation in 
c2c12 cells
Pluripotent C2C12 cells in the presence of 10% fetal calf serum 
(FCS) differentiate to myoblasts (Figure 3A). Treating the cells 
with adipocyte differentiation media pushed the cells towards oil 
droplet rich adipocytes (Figure 3B); however the cells maintained 
their myogenic characteristic (as seen by their ability to contract). 
Both 5 mM (Figure 3C) and 10 mM DMA (Figure 3D) were able 
to reduce the differentiation significantly.
Gene expression of Fabp4 and stearoyl-CoA desaturase (scd-
1), a rate-limiting enzyme in the biosynthesis of fatty acids, was 
TaBle 1 | List of primers used in this study.
gene 
symbol
Product cat. no.:
Rps18 ribosomal protein S18 QT00324940
Fabp4 fatty acid binding protein 4 QT00091532
Pparg peroxisome proliferator activated receptor 
gamma
QT00100296
Cebpa CCAAT/enhancer binding protein (C/EBP), 
alpha
QT00395010
Adipoq Adiponectin QT01169343
Scd1 stearoyl-Coenzyme A desaturase 1 QT00291151
Il6 interleukin 6 QT00098875
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FIgUre 1 | 3T3-L1 cells were differentiated to adipocytes in the presence or absence of DMA. (a, B) DMA was applied throughout with the induction media (IM) and 
differentiation media (DM) from day 0 to day 10. (c, D) DMA was applied throughout the differentiation media (DM) from day 2 to day 10. (e, F) DMA was applied only 
once with the induction media (IM) on day 0. (g, H) DMA was applied to the differentiated 3T3-L1 adipocytes from day 10 to day 20. The sketch indicates the period 
of differentiation and bold arrows indicate the points of DMA treatment. MDIR (3-isobutyl-1 methylxanthine, dexamethasone, insulin and rosiglitazone) was added in 
absence or presence of 5mM or 10mM DMA. Controls were without MDIR and without or with DMA. The red staining indicates the staining by Oil-red O. The staining 
was eluted, absorbance was measured and represented graphically. *p ≤ 0.05 vs. MDIR; **p ≤ 0.05 vs. MDIR with 5 mM DMA, n = 3 independent experiments.
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significantly reduced in the presence of DMA (Figures 3E, F). 
Interestingly, the expression of adiponectin was also reduced 
(Figure 3H) but the expression of PPARγ was a not affected 
(Figure 3G).
DMa Prevents High-Fat Diet-Induced 
Increase in Body Weight
Mice fed with standard chow and injected with DMA once 
a week gained body weight similar to the PBS treated animals 
(Figure 4A). Moreover, the weekly standard chow food intake 
(kcal) was similar between the mice treated with DMA or PBS 
(Figure 4B). Mice fed with high-fat diet (HFD) for 20 weeks 
had a significant higher body weight (Figure 4C) even when 
the weekly food intake (in kcal) was similar between HFD and 
standard chow groups (Figure 4D). When DMA was injected 
intraperitoneally once a week to HFD-fed mice, the body weight 
was significantly lowered by 10 weeks (Figure 4E). In HFD-fed 
mice when PBS was switched to DMA treatment at 10 weeks, the 
rise in body weight was controlled while in PBS treated mice the 
body weight kept increasing (Figure 4G). The lower body weight 
observed in the DMA-treated group in the presence of HFD until 
10 weeks did not sustain when it was switched to PBS (Figure 
4I). Interestingly, the weekly HFD food intake (kcal) was similar 
between the PBS and DMA treatment groups (Figures 4F, H, J), 
suggesting that the changes in body weight were independent of 
the calories consumed.
DMa reduced adipocyte Hypertrophy
Epididymal adipose tissue from mice fed with standard chow 
and treated with PBS or DMA had similar adipocyte number 
and size (Figures 5A–C). However, epididymal fat from HFD-
fed mice had an increased adipocyte area and a lower adipocyte 
number compared with the epididymal fat from standard chow 
fed mice. Interestingly, epididymal fat from mice fed with HFD 
and either treated with PBS and then DMA or vice versa had 
a decreased adipocyte cell size and a concomitant increase in 
adipocyte number in both treatment groups. (Figures 5A–C). 
A similar trend was also seen in adipocytes from subcutaneous 
adipose tissue. The increased adipocyte size and decreased 
adipocyte number from subcutaneous fat of mice fed with HFD 
was reversed in the presence of early or late treatment with DMA 
(Figures 5D–F).
FIgUre 2 | Gene expression of 3T3-L1 adipocytes. DMA (5 mM or 10 mM) was applied to 3T3-L1 cells throughout with the induction and differentiation media 
from day 0 to day 10. After day 10, RNA was extracted and gene expression of Fabp4, Pparγ, Il-6 and adiponectin was analyzed. RNA was extracted from 3 
independent experiments. *p ≤ 0.05 vs. MDIR.
Frontiers in Pharmacology | www.frontiersin.org October 2019 | Volume 10 | Article 1274
DMA and Body WeightBhattacharya et al.
6
FIgUre 3 | C2C12 cells were treated with MDIR in the absence or presence of DMA. The cells treated without MDIR differentiated to myotubes (a). In the presence 
of MDIR, the cells developed lipid droplets but they still maintained the myotube characteristic (B). With MDIR and 5mM DMA, the cells still had lipid droplets but in 
lesser proportion (c). MDIR with 10 mM DMA did not have lipid droplets (D). The photographs are representative of 3 independent experiments. Gene expression of 
C2C12 cells post-differentiation showed a decrease in expression of Fabp4 (e), Scd-1 (F) and adiponectin (H) with 5mM and 10mM DMA. The expression of Pparγ 
(g) was unaltered. *p ≤ 0.05 vs. MDIR; n = 3.
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FIgUre 4 | DMA prevented body weight gain in C57BL/6J mice fed with high-fat diet. Mice were fed with normal diet (ND) for 20 weeks and were injected once 
a week with either DMA or PBS. The body weight in grams (a) and the weekly food intake in kcal (B) was measured. On feeding the mice with HFD, the body 
weight was increased (c) however food intake (in kcal) remained similar (D). Animals treated with DMA had lesser gain in body weight already after 10 weeks in the 
presence of HFD (e) and the food intake was similar between the groups (F). When mice treated with PBS for 10 weeks were switched to DMA treatment for the 
next 10 weeks, the body weight increase was prevented even in the presence of HFD (g). When mice treated with DMA for 10 weeks, were switched to PBS the 
body weight increased (I). Food intake was similar across the groups (H–J). *p ≤ 0.05, n = 5–6 mice/group.
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FIgUre 5 | Increased adipocyte cell size was reduced with DMA treatment in epididymal (a) and subcutaneous adipose tissue (D). Histological sections of 
epididymal and subcutaneous adipose tissue stained with H&E showed no difference in adipocyte cell number (B, e) and size (c, F) from mice fed normal diet and 
treated with either PBS or DMA. The epididymal and subcutaneous adipocyte area was significantly bigger from HFD fed mice (c, F) and the number of cells within 
a 100µm frame were quantitatively less (B, e). Treatment with early DMA or late DMA reversed the increased adipocyte size with a parallel reduction in the adipocyte 
number. *p ≤ 0.05 vs. PBS-treated normal diet; #p ≤ 0.05 vs. PBS-treated HFD. n = 5–6 mice/group.
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DMa reduces Fabp4 gene expression in 
adipose Tissue
The increased expression of Fabp4 in the epididymal adipose 
tissue from mice fed with HFD was significantly lowered by 
treatment with DMA (Figure 6). Other adipocyte markers 
(Pparγ, Cebp1α, Scd-1, and adiponectin) were not altered in the 
epididymal fat by DMA treatment.
Increased Blood glucose Is Improved by 
early DMa Treatment
Mice fed with HFD showed increased glucose levels as 
compared to normal diet fed mice. Interestingly, mice on HFD 
but treated with DMA from the beginning had an improved 
glucose clearance as compared to those treated with DMA 
after 10 weeks (Figure 7A).
FIgUre 6 | Gene expression from epididymal adipose tissue of mice fed with HFD and treated with either PBS or DMA. Only Fabp4 was significantly reduced in 
DMA treated mice. Other genes such as Pparγ, Cebpα, Scd-1 and adiponectin was not altered. *p ≤ 0.05 vs. PBS, n = 5 mice samples/group.
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Increased liver adiposity
The liver samples from the mice fed with HFD and treated 
with PBS developed fatty liver. The HFD-fed mice treated 
with DMA indicated reduced deposition of lipid droplets 
(Figure 7B).
early DMa Treatment results in Improved 
Triglyceride levels
Mice on normal diet and treated with DMA for 20 weeks, 
had reduced triglyceride levels in plasma. Interestingly, the 
triglyceride levels in HFD mice were reduced only by early 
FIgUre 7 | Glucose tolerance test to measure blood glucose levels (mmol/L) in mice fed with either normal diet or HFD and treated with PBS or DMA (a). *p ≤ 0.05 
vs. ND_PBS (n = 3 mice/group). Histological analysis with H&E staining indicated that the HFD fed mice had fatty liver (B). There was a reduced fat cell formation in the 
mice fed with HFD and treated with DMA n = 5–6 mice samples/group. The plasma triglyceride levels were reduced in mice treated with DMA in the presence of normal 
diet (c). *p ≤ 0.05 vs. ND_PBS (n = 3). The HFD-fed mice had reduced triglyceride levels only when DMA was treated early (C) **p ≤ 0.05 vs. HFD_PBS (n = 3).
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treatment of DMA (Figure 7C) and no effect was seen by late 
DMA treatment.
DIscUssION
Tackling the increasing trends of obesity and the associated 
health issues such as type 2 diabetes, blood pressure and cancer 
is a major challenge. Many of these lifestyle-triggered conditions 
can be taken care of, controlled or prevented by altering and 
practicing lifestyle, which involves inculcating stress-free habits, 
eating healthy and moving regularly. However, the role of 
molecular intervention along with the positive lifestyle practices 
cannot be undermined.
In a previous work from our group using ovariectomized rats, 
we showed that the increased body weight induced by ovariectomy 
was reduced after treatment with DMA (Ghayor et  al., 2017). 
In this present work, we have used diet-induced obesity as a more 
general and hormone independent overweight/obesity mouse 
model, which is a well-accepted model for studying obesity 
(Bhattacharya et al., 2008). In the present work, we dwelled 
deep to know if DMA intervened with the body weight increase 
induced by HFD feeding, a condition often associated with 
unhealthy lifestyle. We show that the small molecule DMA has 
the ability to intervene and control the increase in body weight 
induced by HFD (Figure 4), and reduce adipocyte hypertrophy 
(cell size). Moreover, the reduced adipocyte hypertrophy in both 
epididymal and subcutaneous adipose tissue was maintained 
even when the DMA treatment was discontinued. Thus, the 
findings suggest that DMA is a potential therapeutic candidate 
against HFD-induced adiposity.
DMA is a ligand for bromodomains and it is known to reduce 
LPS-induced expression of inflammatory cytokines in cell lines 
(Ghayor et al., 2017; Gorasiya et al., 2018; Pekson et al., 2016). 
Obesity is a low grade chronic inflammation and amongst the 
various inflammatory molecules, the levels of IL-6 is increased 
in the serum of obese patients (Roytblat et al., 2000). Our 
results with 3T3-L1 adipocytes show that the basal expression 
of inflammatory molecule IL-6 was lowered by DMA in a 
concentration-dependent manner (Figure 2).
Increased inflammation is often associated with the 
expression of fatty acid binding protein (Fabp4), a molecule that 
is significantly elevated in morbid obese individuals. Fabp is a 
small cytoplasmic lipid binding protein and is known to mediate 
fatty acid transportation, trafficking and metabolism. Increased 
expression of FABP has been shown to mediate age-related 
inflammation and metabolic diseases (Charles et al., 2017). The 
plasma FABP4 levels have been reported to be upregulated in 
obese patients and positively correlate with BMI and insulin 
resistance (Terra et al., 2011). In our study, the increased 
expression of Fabp4 (also known as alipoprotein2), was reduced 
consistently by DMA in epididymal adipose tissue, 3T3-L1 and 
C2C12 cells. Calorie-restriction which is opposite to ad libitum 
high-fat diet feeding improves overall metabolic health in mice. 
Interestingly, calorie restriction and Fabp deficiency share 
many common molecular features (Charles et al., 2017). Since 
the elevated levels of Fabps have been implicated in obesity, 
diabetes and atherosclerosis therefore molecular inhibitors 
for Fabps are of therapeutic interest (Furuhashi et al., 2007; 
Floresta et al., 2017). And indeed small molecule inhibitor for 
FABP4 have shown to also reduce inflammation (Gong et al., 
2018). In this regard, reduced Fabp4 expression by DMA is of 
importance and can be explored to treat diseases where FABP4 
expression is upregulated.
  PPARγ is a master regulator of adipogenesis and aids in the 
induction and formation of mature adipocytes. It has been 
suggested that the expression of PPARγ is not extremely 
critical in maintaining mature adipocytes (Moseti et al., 2016). 
On the contrary, FABP4 expression is more stable in mature 
adipocytes. Additionally, in adipose tissues high expression 
levels of FABP4 reduces the expression of PPARγ (Garin-
Shkolnik et al., 2014). These may be some factors on why we 
could not detect any change in PPARγ gene expression in the 
presence of DMA, Moreover, the other added reasons may be:
 1. Type of cells- The reduction in PPARγ expression by DMA was 
only evident in adipocytes (3T3-L1) and not in pluoripotent 
cells (C2C12) and in adipose tissue, which is a mix of many 
cells type.
 2. Sensitivity- There may only be a small reduction in the 
expression of PPARγ by DMA and this was only detected in 
adipocyte specific 3T3-L1 cell line.
We did see a consistent decrease in FABP4 expression in 
the presence of DMA in all the three models investigated. 
PPARγ is known to regulate the expression of FABP4, however 
other pathways such as inflammation also regulate FABP4 
expression. Work from our group (Ghayor et al., 2017), has 
shown that DMA reduces the inflammation and probably this 
reduction in inflammation has a contribution in the reduction 
of FABP4 expression.
Adiponectin is not only expressed in adipocytes but it is also 
known to be expressed in soleus muscles and in C2C12 myoblasts 
(Goto et al., 2013). In our study, C2C12 cells when treated with 
adipogenic media took up the lipid droplets but maintained muscle 
contractile characteristic. Adiponectin is generally accepted as an 
anti-inflammatory molecule and its levels are reduced with increased 
body weight in both animal models and in humans (Ouchi and 
Walsh 2007; Nigro et al., 2014). However, in this work, treatment 
with DMA lowered adiponectin levels in C2C12 myotubes, without 
affecting its expression in 3T3-L1 adipocytes and epididymal 
adipose tissue. More recently, the term adiponectin paradox came to 
the fore, which suggests that cardioprotective effect of adiponectin 
is also associated with adiponectin-dependent increase in advanced 
cardiovascular disease pathogenesis (Woodward et al., 2017). In 
skeletal muscles and in C2C12 myotubes, inflammatory cytokines 
has been reported to increase the levels of adiponectin via inducible 
nitric oxide synthase (iNOS) (Delaigle et al., 2004). This suggests 
that adiponectin possibly plays an inflammatory role depending on 
the cellular context. Thus the lowering of adiponectin expression 
by DMA in C2C12 fatty myotubes, in this study, may be related 
to the possible inflammatory effect that adiponectin influences in 
these myotubes.
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The findings with 3T3-L1 cells indicate that the long-term 
treatment with DMA not only inhibits the differentiation of 
adipocytes but also reduce the matured adipocytes, as indicated 
by reduction in Oil red O staining. Indeed, only one-time 
application of DMA even at high concentration (10 mM) did 
not inhibit adipogenesis in 3T3-L1 cells. Our results with cell 
culture showing that the continuous DMA treatment has an 
effective anti-adipogenic effect was also reflective in the mouse 
experiments. When DMA treatment was switched to PBS, the 
body weight of the animals that was under check by DMA, under 
HFD feeding, was altered thus indicating that continuous DMA 
treatment is essential to prevent weight gain. In summary, the 
in vitro and in vivo results suggest that DMA application has 
to be sustained to obtain a strong and effective anti-adipogenic 
response and to reduce adiposity even in the presence of HFD.
DMA is FDA approved drug carrier solvent and has been 
reported to have no toxic effect in humans. Pediatric patients 
with myeloid leukemia when given DMA intravenously to deliver 
busulfan reported no accumulation of DMA in the body (Hempel 
et al., 2007). Moreover, the dose of DMA applied was in the range 
of 70 mM, which was far higher than what we have used in our 
study. In the present work, the dose for DMA was based on our 
earlier work with rats (Ghayor et al., 2017) from our group and 
initially chosen based on the work by Bartsch et  al. (1976). The 
authors suggest that in mice DMA administration via i.p. route 
should not be more than 1/4th the LD50 for DMA. Moreover, the 
concentrations used for DMA in the cell lines was based on an 
earlier work from our group with NMP (Gjoksi et al., 2016)
Our findings indicate that the metabolic parameters such as 
blood glucose levels and triglyceride levels were improved only 
when DMA was given early to the animals in the presence of 
HFD. This suggests that once the insulin resistant state or high 
triglyceride levels are established by HFD feeding, it is then 
difficult for DMA to revert it back to the normal. However, 
further work and other metabolic parameters need to be looked 
at to get a more conclusive answer.
The animals used in the study were 26 weeks old (at the end 
of the experiment), thus studies with older mice fed with HFD 
diet will provide us clearer information on the effect of DMA on 
adulthood obesity. These studies will also provide us information 
if DMA affects longevity. Since DMA was able to significantly 
reduce Fabp expression, this study provides hints to use DMA in 
other disease models like atherosclerosis where Fabp expression 
is enhanced (Tu et al., 2017).
In conclusion, the findings of this study suggest that DMA has 
a strong potential to control adiposity and prevent the fat-related 
increase in body weight contributed by HFD feeding. This would 
contribute in preventing overweight/obesity in the presence of 
unhealthy food intake. Hence, we propose DMA as a potential 
therapeutic candidate against weight gain/obesity and diseases 
associated with it based on the available data.
DaTa aVaIlaBIlITY sTaTeMeNT
All datasets generated for this study are included in the article/
supplementary material.
aUTHOr cONTrIBUTIONs
IB, CG, and FW designed experiments. IB, AP, and CG 
performed the experiments. IB analyzed the data. IB and FW 
wrote the manuscript.
FUNDINg
The research work was supported by grants from Swiss National 
Science Foundation to FW. 
acKNOWleDgMeNTs
We thank Nupur Khera, Anja Ivica and Tse-Hsiang Chen for 
providing help and experimental support during the course of 
the study. All animal work was kindly supported by Flora Nichols.
reFereNces
Bartsch, W., Sponer, G., Dietmann, K., and Fuchs, G. (1976).Acute toxicity of 
various solvents in the mouse and rat. LD50 of ethanol, diethylacetamide, 
dimethylformamide, dimethylsulfoxide, glycerine, N-methylpyrrolidone, 
polyethylene glycol 400, 1,2-propanediol and Tween 20. Arzneimittelforschung 
26, 1581–1583. 
Bhattacharya, I., Dominguez, A. P., Dragert, K., Humar, R., Haas, E., and 
Battegay, E. J. (2015).Hypoxia potentiates tumor necrosis factor-alpha induced 
expression of inducible nitric oxide synthase and cyclooxygenase-2 in white 
and brown adipocytes. Biochem. Biophys. Res. Commun. 461, 287–292. doi: 
10.1016/j.bbrc.2015.04.020
Bhattacharya, I., Mundy, A. L., Widmer, C. C., Kretz, M., and Barton, M. (2008).
Regional heterogeneity of functional changes in conduit arteries after high-fat 
diet. Obesity (Silver Spring) 16, 743–748. doi: 10.1038/oby.2007.111
Cao, J. J., Sun, L., and Gao, H. (2010). Diet-induced obesity alters bone remodeling 
leading to decreased femoral trabecular bone mass in micey. Ann. N. Y. Acad. 
Sci. 1192, 292–297. doi: 10.1111/j.1749-6632.2009.05252.x
Charles, K. N., Li, M. D., Engin, F., Arruda, A. P., Inouye, K., and Hotamisligil, 
G. S. (2017).Uncoupling of metabolic health from longevity through genetic 
alteration of adipose tissue lipid-binding proteins. Cell Rep. 21, 393–402. doi: 
10.1016/j.celrep.2017.09.051
Delaigle, A. M., Jonas, J. C., Bauche, I. B., Cornu, O., and Brichard, S. M. (2004).
Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo 
and in vitro studies. Endocrinology 145, 5589–5597. doi: 10.1210/en.2004-0503
Floresta, G., Pistara, V., Amata, E., Dichiara, M., Marrazzo, A., Prezzavento, 
O., et al. (2017).Adipocyte fatty acid binding protein 4 (FABP4) inhibitors. 
A comprehensive systematic review. Eur. J. Med. Chem. 138, 854–873. doi: 
10.1016/j.ejmech.2017.07.022
Foreman, K. J., Marquez, N., Dolgert, A., Fukutaki, K., Fullman, N., McGaughey, 
M., et al. (2018).Forecasting life expectancy, years of life lost, and all-cause 
and cause-specific mortality for 250 causes of death: reference and alternative 
scenarios for 2016-40 for 195 countries and territories. Lancet 392, 2052–2090. 
doi: 10.1016/S0140-6736(18)31694-5
Furuhashi, M., Tuncman, G., Gorgun, C. Z., Makowski, L., Atsumi, G., 
Vaillancourt, E., et al. (2007).Treatment of diabetes and atherosclerosis by 
Frontiers in Pharmacology | www.frontiersin.org October 2019 | Volume 10 | Article 1274
DMA and Body WeightBhattacharya et al.
13
inhibiting fatty-acid-binding protein aP2. Nature 447, 959–965. doi: 10.1038/
nature05844
Garin-Shkolnik, T., Rudich, A., Hotamisligil, G. S., and Rubinstein, M. (2014). 
FABP4 attenuates PPARgamma and adipogenesis and is inversely correlated with 
PPARgamma in adipose tissues. Diabetes 63, 900–911. doi: 10.2337/db13-0436
Ghayor, C., Gjoksi, B., Dong, J., Siegenthaler, B., Caflisch, A., and Weber, F. E. 
(2017). N,N Dimethylacetamide a drug excipient that acts as bromodomain 
ligand for osteoporosis treatment. Sci. Rep. 7, 42108. doi: 10.1038/srep42108
Gjoksi, B., Ghayor, C., Bhattacharya, I., Zenobi-Wong, M., and Weber, F. E. (2016).
The bromodomain inhibitor N-methyl pyrrolidone reduced fat accumulation 
in an ovariectomized rat model. Clin. Epigenetics 8, 42. doi: 10.1186/
s13148-016-0209-2
Gong, Y., Yu, Z., Gao, Y., Deng, L., Wang, M., Chen, Y., et al. (2018). FABP4 
inhibitors suppress inflammation and oxidative stress in murine and cell 
models of acute lung injury. Biochem. Biophys. Res. Commun. 496, 1115–1121. 
doi: 10.1016/j.bbrc.2018.01.150
Gorasiya, S., Mushi, J., Pekson, R., Yoganathan, S., Reznik, S. E., and Repurposing, 
N. (2018). N-Dimethylacetamide (DMA), a pharmaceutical excipient, as a 
prototype novel anti-inflammatory agent for the prevention and/or treatment 
of preterm birth. Curr. Pharm. Des. 24, 989–992. doi: 10.2174/1381612824666
180130121706
Goto, A., Ohno, Y., Ikuta, A., Suzuki, M., Ohira, T., Egawa, T., et al. (2013).
Up-regulation of adiponectin expression in antigravitational soleus muscle in 
response to unloading followed by reloading, and functional overloading in 
mice. PLoS One 8, e81929. doi: 10.1371/journal.pone.0081929
Hempel, G., Oechtering, D., Lanvers-Kaminsky, C., Klingebiel, T., Vormoor,  J., 
Gruhn, B., et al. (2007).Cytotoxicity of dimethylacetamide and pharmacokinetics 
in children receiving intravenous busulfan. J. Clin. Oncol. 25, 1772–1778. doi: 
10.1200/JCO.2006.08.8807
Hsu, Y. H., Venners, S. A., Terwedow, H. A., Feng, Y., Niu, T., Li, Z., et al. (2006).
Relation of body composition, fat mass, and serum lipids to osteoporotic 
fractures and bone mineral density in Chinese men and women. Am. J. Clin. 
Nutr. 83, 146–154. doi: 10.1093/ajcn/83.1.146
Moseti, D., Regassa, A., and Kim, W. K. (2016). Molecular regulation of 
adipogenesis and potential anti-adipogenic bioactive molecules. Int. J. Mol. Sci. 
17, 124. doi: 10.3390/ijms17010124
Mundy, A. L., Haas, E., Bhattacharya, I., Widmer, C. C., Kretz, M., Hofmann-
Lehmann, R., et al. (2007).Fat intake modifies vascular responsiveness and 
receptor expression of vasoconstrictors: implications for diet-induced obesity. 
Cardiovasc. Res. 73, 368–375. doi: 10.1016/j.cardiores.2006.11.019
Ng, M., Fleming, T., Robinson, M., Thomson, B., Graetz, N., Margono, C., et al. 
(2014).Global, regional, and national prevalence of overweight and obesity 
in children and adults during 1980-2013: a systematic analysis for the 
Global Burden of Disease Study 2013. Lancet 384, 766–781. doi: 10.1016/
S0140-6736(14)60460-8
Nigro, E., Scudiero, O., Monaco, M. L., Palmieri, A., Mazzarella, G., Costagliola, C., 
et al. (2014).New insight into adiponectin role in obesity and obesity-related 
diseases. Biomed. Res. Int. 2014, 658913. doi: 10.1155/2014/658913
Oh, M., Kim, S., An, K. Y., Min, J., Yang, H. I., Lee, J., et al. (2018).Effects of 
alternate day calorie restriction and exercise on cardio-metabolic risk factors 
in overweight and obese adults: an exploratory randomized controlled study. 
BMC Public Health 18, 1124. doi: 10.1186/s12889-018-6009-1
Ouchi, N., and Walsh, K. (2007).Adiponectin as an anti-inflammatory factor. Clin. 
Chim. Acta 380, 24–30. doi: 10.1016/j.cca.2007.01.026
Pekson, R., Poltoratsky, V., Gorasiya, S., Sundaram, S., Ashby, C. R., Vancurova, I., 
et al. (2016). N,N-Dimethylacetamide significantly attenuates LPS- and 
TNFalpha-induced proinflammatory responses via inhibition of the 
nuclear factor kappa B pathway. Mol. Med. 22, 747–758. doi: 10.2119/
molmed.2016.00017
Qi, R., Liu, H., Wang, Q., Wang, J., Yang, F., Long, D., et al. (2017).Expressions 
and regulatory effects of P38/ERK/JNK Mapks in the adipogenic trans-
differentiation of C2C12 myoblasts. Cell Physiol. Biochem. 44, 2467–2475. doi: 
10.1159/000486169
Roytblat, L., Rachinsky, M., Fisher, A., Greemberg, L., Shapira, Y., Douvdevani, A., 
et al. (2000).Raised interleukin-6 levels in obese patients. Obes. Res. 8, 673–675. 
doi: 10.1038/oby.2000.86
Rudman, H. A., Birrell, F., Pearce, M. S., Tuck, S. P., Francis, R. M., Treadgold, L., 
et  al. (2019). Obesity, bone density relative to body weight and prevalent 
vertebral fracture at age 62 years: the Newcastle thousand families study. 
Osteoporos. Int. 30, 829–836. doi: 10.1007/s00198-018-04817-3
Shapses, S. A., Pop, L. C., and Wang, Y. (2017).Obesity is a concern for bone health 
with aging. Nutr. Res. 39, 1–13. doi: 10.1016/j.nutres.2016.12.010
Styner, M., Pagnotti, G. M., McGrath, C., Wu, X., Sen, B., Uzer, G., et al. (2017).
Exercise decreases marrow adipose tissue through ss-oxidation in obese 
running mice. J. Bone Miner. Res. 32, 1692–1702. doi: 10.1002/jbmr.3159
Terra, X., Quintero, Y., Auguet, T., Porras, J. A., Hernandez, M., Sabench, F., 
et al. (2011). FABP 4 is associated with inflammatory markers and metabolic 
syndrome in morbidly obese women. Eur. J. Endocrinol. 164, 539–547. doi: 
10.1530/EJE-10-1195
Tu, W. J., Zeng, X. W., Deng, A., Zhao, S. J., Luo, D. Z., Ma, G. Z., et al. (2017). 
Circulating FABP4 (Fatty Acid-Binding Protein 4) is a novel prognostic 
biomarker in patients with acute ischemic stroke. Stroke 48, 1531–1538. doi: 
10.1161/STROKEAHA.117.017128
Villareal, D. T., Kotyk, J. J., Armamento-Villareal, R. C., Kenguva, V., Seaman, 
P., Shahar, A., et al. (2011).Reduced bone mineral density is not associated 
with significantly reduced bone quality in men and women practicing long-
term calorie restriction with adequate nutrition. Aging Cell 10, 96–102. doi: 
10.1111/j.1474-9726.2010.00643.x
Woodward, L., Akoumianakis, I., and Antoniades, C. (2017).Unravelling 
the adiponectin paradox: novel roles of adiponectin in the regulation of 
cardiovascular disease. Br. J. Pharmacol. 174, 4007–4020. doi: 10.1111/
bph.13619
Conflict of Interest: The authors declare that the research was conducted in the 
absence of any commercial or financial relationships that could be construed as a 
potential conflict of interest.
Copyright © 2019 Bhattacharya, Ghayor, Pérez Dominguez and Weber. This 
is an open-access article distributed under the terms of the Creative Commons 
Attribution License (CC BY). The use, distribution or reproduction in other forums 
is permitted, provided the original author(s) and the copyright owner(s) are 
credited and that the original publication in this journal is cited, in accordance 
with accepted academic practice. No use, distribution or reproduction is 
permitted which does not comply with these terms.
Frontiers in Pharmacology | www.frontiersin.org October 2019 | Volume 10 | Article 1274
